FDA Approves Replimune's Melanoma Drug On Third Attempt

WSJ News Agency

3 hours ago•WSJ

Stocks Medium Importance Neutral

FDA Approves Replimune's Melanoma Drug On Third Attempt

The agency had turned down two earlier applications over clinical data-quality concerns.

Related Symbols 1

R REPL REPL

Source: WSJ

Visit Source

0 0 0

Comment

Comments

No comments yet

Be the first person to comment on this news item.

Category Stocks

Source WSJ

Published 3 hours ago

Likes 0

Comments 0

Shares 0

News ID #2,378

Status Published

This news may have been collected automatically from third-party sources. Please verify important information through the original source and other reliable sources before making any trading or investment decision. This content is provided for informational purposes only and does not constitute financial advice.

Keep comments relevant to the news topic and avoid offensive, promotional, spam, or misleading content.

FDA Approves Replimune's Melanoma Drug On Third Attempt

Comments

User Menu